BACKGROUND: Fabry disease (FD), an X-linked lysosomal storage disorder, is caused by a reduced activity of the lysosomal enzyme alpha-galactosidase A. The disorder ultimately leads to organ damage (including renal failure) in males and females. However, heterozygous females usually present a milder phenotype with a later onset and a slower progression. METHODS: A combined enzymatic and genetic strategy was used, measuring the activity of alpha-galactosidase A and genotyping the alpha-galactosidase A gene (GLA) in dried blood samples (DBS) of 911 patients undergoing haemodialysis in centers across Spain. RESULTS: GLA alterations were found in seven unrelated patients (4 males and 3 females). Two novel mutations (p.Gly346AlafsX347 and p.Val199GlyfsX203) were identified as well as a previously described mutation, R118C. The R118C mutation was present in 60% of unrelated patients with GLA causal mutations. The D313Y alteration, considered by some authors as a pseudo-deficiency allele, was also found in two out of seven patients. CONCLUSIONS: Excluding the controversial D313Y alteration, FD presents a frequency of one in 182 individuals (0.55%) within this population of males and females undergoing haemodialysis. Moreover, our findings suggest that a number of patients with unexplained and atypical symptoms of renal disease may have FD. Screening programmes for FD in populations of individuals presenting severe kidney dysfunction, cardiac alterations or cerebrovascular disease may lead to the diagnosis of FD in those patients, the study of their families and eventually the implementation of a specific therapy.
BACKGROUND:Fabry disease (FD), an X-linked lysosomal storage disorder, is caused by a reduced activity of the lysosomal enzyme alpha-galactosidase A. The disorder ultimately leads to organ damage (including renal failure) in males and females. However, heterozygous females usually present a milder phenotype with a later onset and a slower progression. METHODS: A combined enzymatic and genetic strategy was used, measuring the activity of alpha-galactosidase A and genotyping the alpha-galactosidase A gene (GLA) in dried blood samples (DBS) of 911 patients undergoing haemodialysis in centers across Spain. RESULTS:GLA alterations were found in seven unrelated patients (4 males and 3 females). Two novel mutations (p.Gly346AlafsX347 and p.Val199GlyfsX203) were identified as well as a previously described mutation, R118C. The R118C mutation was present in 60% of unrelated patients with GLA causal mutations. The D313Y alteration, considered by some authors as a pseudo-deficiency allele, was also found in two out of seven patients. CONCLUSIONS: Excluding the controversial D313Y alteration, FD presents a frequency of one in 182 individuals (0.55%) within this population of males and females undergoing haemodialysis. Moreover, our findings suggest that a number of patients with unexplained and atypical symptoms of renal disease may have FD. Screening programmes for FD in populations of individuals presenting severe kidney dysfunction, cardiac alterations or cerebrovascular disease may lead to the diagnosis of FD in those patients, the study of their families and eventually the implementation of a specific therapy.
Authors: Y Nagao; H Nakashima; Y Fukuhara; M Shimmoto; A Oshima; Y Ikari; Y Mori; H Sakuraba; Y Suzuki Journal: Clin Genet Date: 1991-03 Impact factor: 4.438
Authors: W von Scheidt; C M Eng; T F Fitzmaurice; E Erdmann; G Hübner; E G Olsen; H Christomanou; R Kandolf; D F Bishop; R J Desnick Journal: N Engl J Med Date: 1991-02-07 Impact factor: 91.245
Authors: S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba Journal: N Engl J Med Date: 1995-08-03 Impact factor: 91.245
Authors: Makiko Yasuda; Junaid Shabbeer; Stacy D Benson; Irene Maire; Roger M Burnett; Robert J Desnick Journal: Hum Mutat Date: 2003-12 Impact factor: 4.878
Authors: G E Linthorst; M G Bouwman; F A Wijburg; J M F G Aerts; B J H M Poorthuis; C E M Hollak Journal: J Med Genet Date: 2009-09-24 Impact factor: 6.318
Authors: Markus Niemann; Arndt Rolfs; Anne Giese; Hermann Mascher; Frank Breunig; Georg Ertl; Christoph Wanner; Frank Weidemann Journal: JIMD Rep Date: 2012-07-01
Authors: Susana Ferreira; Alberto Ortiz; Dominique P Germain; Miguel Viana-Baptista; António Caldeira-Gomes; Marta Camprecios; Maria Fenollar-Cortés; Ángel Gallegos-Villalobos; Diego Garcia; José Antonio García-Robles; Jesús Egido; Eduardo Gutiérrez-Rivas; José Antonio Herrero; Sebastián Mas; Raluca Oancea; Paloma Péres; Luis Manuel Salazar-Martín; Jesús Solera-Garcia; Helena Alves; Scott C Garman; João Paulo Oliveira Journal: Mol Genet Metab Date: 2014-11-09 Impact factor: 4.797
Authors: Laura Fancellu; Walter Borsini; Ilaria Romani; Angelo Pirisi; Giovanni Andrea Deiana; Elia Sechi; Pietro Emiliano Doneddu; Anna Laura Rassu; Rita Demurtas; Anna Scarabotto; Pamela Cassini; Eloisa Arbustini; GianPietro Sechi Journal: BMC Neurol Date: 2015-12-12 Impact factor: 2.474
Authors: S Sirrs; C Hollak; M Merkel; A Sechi; E Glamuzina; M C Janssen; R Lachmann; J Langendonk; M Scarpelli; T Ben Omran; F Mochel; M C Tchan Journal: JIMD Rep Date: 2015-10-09
Authors: Andreas D Kistler; Justyna Siwy; Frank Breunig; Praveen Jeevaratnam; Alexander Scherl; William Mullen; David G Warnock; Christoph Wanner; Derralynn A Hughes; Harald Mischak; Rudolf P Wüthrich; Andreas L Serra Journal: PLoS One Date: 2011-06-15 Impact factor: 3.240
Authors: Malte Lenders; Thomas Duning; Michael Schelleckes; Boris Schmitz; Sonja Stander; Arndt Rolfs; Stefan-Martin Brand; Eva Brand Journal: PLoS One Date: 2013-02-05 Impact factor: 3.240